Vivani Medical (VANI) Projected to Post Earnings on Monday

Vivani Medical (NASDAQ:VANI) is expected to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Vivani Medical to post earnings of ($0.10) per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, April 3, 2026 at 9:30 AM ET.

Vivani Medical Stock Up 0.9%

NASDAQ:VANI opened at $1.16 on Monday. The business’s 50-day moving average price is $1.27 and its 200 day moving average price is $1.36. Vivani Medical has a 52-week low of $0.91 and a 52-week high of $1.92. The firm has a market cap of $90.68 million, a P/E ratio of -2.58 and a beta of 3.17.

Insider Transactions at Vivani Medical

In other Vivani Medical news, Director Gregg Williams acquired 1,575,231 shares of the firm’s stock in a transaction on Sunday, March 15th. The stock was purchased at an average cost of $1.07 per share, for a total transaction of $1,685,497.17. Following the transaction, the director owned 31,357,183 shares of the company’s stock, valued at $33,552,185.81. The trade was a 5.29% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders bought 4,664,347 shares of company stock valued at $5,666,549. 46.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC bought a new stake in shares of Vivani Medical in the 3rd quarter valued at approximately $26,000. Susquehanna International Group LLP raised its position in Vivani Medical by 100.5% during the third quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock valued at $46,000 after acquiring an additional 16,200 shares in the last quarter. Jane Street Group LLC acquired a new stake in Vivani Medical in the fourth quarter valued at approximately $60,000. Renaissance Technologies LLC lifted its stake in Vivani Medical by 118.4% in the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after acquiring an additional 53,127 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in Vivani Medical in the fourth quarter worth approximately $174,000. 6.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $4.00.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.